Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

Robert Kiyosaki predicted AI-driven ‘massive unemployment,’ and 2026 might make him a prophet. What’s behind the layoffs

View original at finance.yahoo.com
Robert Kiyosaki predicted AI-driven ‘massive unemployment,’ and 2026 might make him a prophet. What’s behind the layoffs Gage Skidmore/Wikimedia Commons; Justin Sullivan/Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Work will become optional in the future as AI develops, similar to growing vegetables in your backyard

    60% confidence
  • Gold will soon break through $2,100 and then take off, with next stop being $3,700

    60% confidence
  • Gold will soon break through $2,100 and then take off, with next stop at $3,700

    60% confidence
  • AI could wipe out half of all entry-level white-collar jobs and push unemployment rate as high as 20% in the next one to five years

    60% confidence
  • Investing in talent and AI tools are not mutually exclusive, and many 'AI layoffs' are just companies underperforming or lacking market opportunity

    60% confidence
  • AI will cause many 'smart students' to lose their jobs and cause massive unemployment, with many still having student loan debt

    60% confidence
  • Investing in talent and AI tools are not mutually exclusive, and many AI layoffs are just companies underperforming or lacking bigger market opportunity

    60% confidence
  • Companies are scapegoating AI technology and using it to make good excuses for layoffs, skeptical whether layoffs are due to true efficiency gains

    60% confidence
  • He owns 15,000 houses strictly for investment purposes

    60% confidence
  • Recommends becoming entrepreneurs with at least a side hustle and investing in income-producing real estate for steady cash flow

    60% confidence
  • AI cannot fire him because he does not have a job

    60% confidence
  • He became an entrepreneur investing in real estate, using debt, and saving real gold, silver, and Bitcoin instead of following traditional employment advice

    60% confidence
  • Companies are scapegoating AI to make good excuses for layoffs rather than true efficiency gains

    60% confidence
  • AI could wipe out half of all entry-level white-collar jobs and push unemployment rate as high as 20% in the next one to five years

    60% confidence
  • Work will become optional in the future as AI continues to develop

    60% confidence
  • AI will cause many 'smart students' to lose their jobs and cause massive unemployment, with many still having student loan debt

    60% confidence
  • AI cannot fire him because he does not have a job

    60% confidence
  • People should become entrepreneurs, at least have a side hustle, and not need job security, then invest in income-producing real estate in a crash which provides steady cash flow

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com